The Highs and Lows of ADAMTS13 Activity

被引:0
|
作者
Shaw, Rebecca J. [1 ,2 ]
Abrams, Simon T. [2 ]
Badu, Samuel [1 ]
Toh, Cheng-Hock [1 ,2 ]
Dutt, Tina [1 ]
机构
[1] Liverpool Univ Hosp NHS Fdn Trust, Liverpool L7 8YE, England
[2] Univ Liverpool, Inst Infect Vet & Ecol Sci, Clin Infect Microbiol & Immunol, Ronald Ross Bldg,8 West Derby St, Liverpool L69 7BE, England
关键词
ADAMTS13; TTP; vWF; recombinant; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON-WILLEBRAND-FACTOR; RECOMBINANT ADAMTS13; ANTI-ADAMTS13; AUTOANTIBODIES; RISK; DYSFUNCTION; DEFICIENCY; PROTEASE; SEPSIS; TTP;
D O I
10.3390/jcm13175152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Severe deficiency of ADAMTS13 (<10 iu/dL) is diagnostic of thrombotic thrombocytopenic purpura (TTP) and leads to accumulation of ultra-large vWF multimers, platelet aggregation, and widespread microthrombi, which can be life-threatening. However, the clinical implications of a low ADAMTS13 activity level are not only important in an acute episode of TTP. In this article, we discuss the effects of low ADAMTS13 activity in congenital and immune-mediated TTP patients not only at presentation but once in a clinical remission. Evidence is emerging of the clinical effects of low ADAMTS13 activity in other disease areas outside of TTP, and here, we explore the wider impact of low ADAMTS13 activity on the vascular endothelium and the potential for recombinant ADAMTS13 therapy in other thrombotic disease states.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] ADAMTS13 INHIBITOR ASSESSMENT WITH THE HEMOSIL ACUSTAR ADAMTS13 ACTIVITY ASSAY
    Valsecchi, C.
    Mirabet, M.
    Mancini, I.
    Schiavone, L.
    Mane-Padros, D.
    Peyvandi, F.
    HAEMATOLOGICA, 2019, 104 : 23 - 24
  • [2] ADAMTS13 activity and inhibitor
    Doldan-Silvero, Adriana
    Acevedo-Gadea, Carlos
    Habib, Clandine
    Freeman, Jonathan
    Johari, Vandita
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (10) : 811 - 813
  • [3] ADAMTS13 activity in cryoprecipitate
    Scott, E. A.
    Puca, K. E.
    Pietz, B. C.
    Friedman, K. D.
    TRANSFUSION, 2006, 46 (09) : 12A - 12A
  • [4] ADAMTS13 activity, ADAMTS13 and vWF Antigen concentration and the risk of myocardial infarction
    Vetr, H.
    Geiter, S.
    Graf, M.
    Laemmle, B.
    Redondo, M.
    Binder, B. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 563 - 563
  • [5] Low ADAMTS13 antigen and activity and the presence of ADAMTS13 autoantibody suggest ADAMTS13 may play a role in venous thromboembolism
    Fryer, H. J. L.
    Hoecke, C. J.
    Wu, J. R.
    Guinto, E.
    Greenfield, R. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 426 - 426
  • [6] The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction
    Austin, S. K.
    Starke, R. D.
    Lawrie, A. S.
    Cohen, H.
    Machin, S. J.
    Mackie, I. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) : 536 - 544
  • [7] ADAMTS13 in nephrology [ADAMTS13 in der Nephrologie]
    Bockmeyer C.L.
    Modde F.
    Becker J.U.
    Der Nephrologe, 2013, 8 (1): : 69 - 70
  • [8] Measurement of ADAMTS13 activity and inhibitors
    Miyata, T
    Kokame, K
    Banno, F
    CURRENT OPINION IN HEMATOLOGY, 2005, 12 (05) : 384 - 389
  • [9] Evaluation of an ADAMTS13 activity ELISA
    Butler, J.
    Butler, J. J.
    Malan, E.
    Clifford, J.
    Wheeler, M.
    Gan, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 563 - 563
  • [10] Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays
    Shelat, SG
    Ai, JH
    Zheng, XL
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (06): : 659 - 672